Precision Medicine · us
How Can Cancer Whole-Genome Interpretation Be Made Less Burdensome? Inocras Announces Preliminary AI-Assisted Review Results
Inocras proposes a workflow in which AI handles some cancer genetic variants and refers difficult cases to experts. A preliminary evaluation shows high interpretive concordance, but whether it can save clinical work time while maintaining report quality still requires more comprehensive validation.
Reading a cancer’s whole genome is only the starting point for understanding a tumor. Determining which variants are reliable and which may be involved in cancer development requires reviewing them individually. At the Association for Molecular Pathology (AMP) annual meeting in the United States, Inocras presented preliminary results from an AI-assisted framework intended to reduce the burden of this interpretation process.
According to LabMedica, the framework integrates genomic annotations and sequencing quality information to review candidate variants that may drive cancer. When additional evidence is needed, the system can examine images of sequencing read alignments and query existing internal cases, mimicking how experts cross-check different lines of evidence.
In the evaluation released by the company, variants on which the system made a determination showed 99.5% concordance with expert review; another 10.2% of candidate variants were referred to experts. These two figures must be read together: the concordance rate describes the subset on which the system was willing to make a determination. It cannot be treated directly as the accuracy of identifying all variants, much less as the accuracy of cancer diagnosis.
With the same inputs and settings, repeated analyses showed 98.4% reproducibility. This provides preliminary evidence of workflow stability while leaving practical questions: which variants are prone to receiving different determinations when the analysis is rerun, and how should laboratories ensure that these differences do not affect the final report?
Existing reporting does not specify how many patients and variants the evaluation covered, the distribution of cancer types, or whether independent external data were used for validation. It is therefore still difficult to judge whether the results can be generalized to different laboratories. Agreement with experts also does not necessarily mean that an interpretation is correct. Assessing clinical value still requires clarifying the types of errors and whether they could affect subsequent treatment decisions.
Inocras estimates that the framework could reduce expert review time by more than half, but this benefit remains to be validated, and all clinical reports are still reviewed and signed by personnel. These conference-stage findings propose a testable direction: whether having AI take on some routine review can allow experts to devote more time to difficult cases while maintaining report quality.